奥泰生物(688606)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据奥泰生物三季报分析:

  盈利能力明显恶化,总资产收益能力急剧下降

  成长能力明显恶化,经营业绩承受明显压力

  偿债能力维持稳定,偿还流动负债能力很强

  运营能力明显恶化,总资产利用效率腰斩

  现金流能力明显恶化,可持续经营能力转向恶化

  财务数据
    截至第三季度实现净利润1.01亿元,每股收益1.28元。

    截至第三季度最新股东权益375075.60万元,未分配利润178027.51万元。

    截至第三季度最新总资产404554.75万元,负债29479.15万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入559,938,588.88387,847,292.99236,135,335.173,388,568,140.41
营业总成本437,853,772.09305,909,923.16178,928,268.651,750,302,692.66
营业利润129,101,950.7391,075,967.9246,254,815.881,393,828,395.93
利润总额114,963,243.8477,262,454.146,055,548.681,381,448,333.47
净利润101,246,320.6770,826,854.2440,336,129.331,185,015,695.44
其他综合收益3,883,900.184,758,574.54-280,655.1728,124,725.13
综合收益总额105,130,220.8575,585,428.7840,055,474.161,213,140,420.57
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计3,141,391,344.373,284,683,124.993,948,084,209.494,189,174,367.17
非流动资产合计904,156,113.26745,477,817.6620,071,530.69510,548,813.65
资产总计4,045,547,457.634,030,160,942.594,568,155,740.184,699,723,180.82
流动负债合计266,803,336.42274,159,716.43328,739,728.27510,752,555.05
非流动负债合计27,988,141.9225,072,635.0421,756,564.4918,048,234.98
负债合计294,791,478.34299,232,351.47350,496,292.76528,800,790.03
归属于母公司股东权益合计3,746,472,678.693,726,679,337.084,213,196,753.014,166,522,369.83
股东权益合计3,750,755,979.293,730,928,591.124,217,659,447.424,170,922,390.79
负债和股东权益合计4,045,547,457.634,030,160,942.594,568,155,740.184,699,723,180.82
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计559,872,672.01374,453,347.38178,230,168.163,759,519,068.4
经营活动现金流出小计643,902,542.65494,036,992.95355,905,888.922,398,834,049.55
经营活动产生的现金流量净额-84,029,870.64-119,583,645.57-177,675,720.761,360,685,018.85
投资活动现金流入小计1,422,244,444.451,351,917,283.61797,321,036.672,280,850,235.49
投资活动现金流出小计1,368,611,222.8945,530,317.53717,324,091.713,544,848,354.53
投资活动产生的现金流量净额53,633,221.65406,386,966.0879,996,944.96-1,263,998,119.04
筹资活动现金流入小计8,936,886.08200,000200,0003,700,000
筹资活动现金流出小计567,452,935537,831,434.978,495,694.45365,609,228.25
筹资活动产生的现金流量净额-558,516,048.92-537,631,434.97-8,295,694.45-361,909,228.25
汇率变动对现金及现金等价物的影响12,289,891.9317,657,226.82-6,339,863.2767,859,754.2
现金及现金等价物净增加额-576,622,805.98-233,170,887.64-112,314,333.52-197,362,574.24
期末现金及现金等价物余额1,405,219,967.841,748,671,886.181,869,528,440.31,981,842,773.82
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润1.01亿元,每股收益1.28元。

    截至第三季度最新股东权益375075.60万元,未分配利润178027.51万元。

    截至第三季度最新总资产404554.75万元,负债29479.15万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入559,938,588.88387,847,292.99236,135,335.173,388,568,140.41
营业总成本437,853,772.09305,909,923.16178,928,268.651,750,302,692.66
营业利润129,101,950.7391,075,967.9246,254,815.881,393,828,395.93
利润总额114,963,243.8477,262,454.146,055,548.681,381,448,333.47
净利润101,246,320.6770,826,854.2440,336,129.331,185,015,695.44
其他综合收益3,883,900.184,758,574.54-280,655.1728,124,725.13
综合收益总额105,130,220.8575,585,428.7840,055,474.161,213,140,420.57
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计3,141,391,344.373,284,683,124.993,948,084,209.494,189,174,367.17
非流动资产合计904,156,113.26745,477,817.6620,071,530.69510,548,813.65
资产总计4,045,547,457.634,030,160,942.594,568,155,740.184,699,723,180.82
流动负债合计266,803,336.42274,159,716.43328,739,728.27510,752,555.05
非流动负债合计27,988,141.9225,072,635.0421,756,564.4918,048,234.98
负债合计294,791,478.34299,232,351.47350,496,292.76528,800,790.03
归属于母公司股东权益合计3,746,472,678.693,726,679,337.084,213,196,753.014,166,522,369.83
股东权益合计3,750,755,979.293,730,928,591.124,217,659,447.424,170,922,390.79
负债和股东权益合计4,045,547,457.634,030,160,942.594,568,155,740.184,699,723,180.82
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计559,872,672.01374,453,347.38178,230,168.163,759,519,068.4
经营活动现金流出小计643,902,542.65494,036,992.95355,905,888.922,398,834,049.55
经营活动产生的现金流量净额-84,029,870.64-119,583,645.57-177,675,720.761,360,685,018.85
投资活动现金流入小计1,422,244,444.451,351,917,283.61797,321,036.672,280,850,235.49
投资活动现金流出小计1,368,611,222.8945,530,317.53717,324,091.713,544,848,354.53
投资活动产生的现金流量净额53,633,221.65406,386,966.0879,996,944.96-1,263,998,119.04
筹资活动现金流入小计8,936,886.08200,000200,0003,700,000
筹资活动现金流出小计567,452,935537,831,434.978,495,694.45365,609,228.25
筹资活动产生的现金流量净额-558,516,048.92-537,631,434.97-8,295,694.45-361,909,228.25
汇率变动对现金及现金等价物的影响12,289,891.9317,657,226.82-6,339,863.2767,859,754.2
现金及现金等价物净增加额-576,622,805.98-233,170,887.64-112,314,333.52-197,362,574.24
期末现金及现金等价物余额1,405,219,967.841,748,671,886.181,869,528,440.31,981,842,773.82
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
徐建明435.2211.620.00
陆维克260.776.961.77
宁波文叶创业投资合伙企业(普通合伙)180.334.81-75.65
傅燕萍104.262.780.66
中国银行股份有限公司-国泰江源优势精选灵活配置混合型证券投资基金46.381.2446.38
杭州靖睿投资管理合伙企业(有限合伙)44.401.190.00
国泰佳泰价值平衡股票型养老金产品-中国建设银行股份有限公司42.081.1242.08
姜正金38.071.02-4.29
宓莉33.860.900.00
中国建设银行股份有限公司-国泰医药健康股票型证券投资基金32.240.8632.24
  主力控盘
  公司简介
奥泰生物 所属地域: 浙江省 涉及概念: 沪股通,抗原检测,猴痘概念,肝炎概念,人民币贬值受益,幽门螺杆菌概念,辅助生殖,融资融券,新冠检测,医疗器械概念
主营业务: 许可项目:第二类医疗器械生产;第三类医疗器械生产;第三类医疗器械经营;货物进出口;技术进出口。(依法须经批准的项目,经相关部门批准后方可开展经营活动,具体经营项目以相关部门批准文件或许可证件为准)。一般项目:技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广;第一类医疗器械生产;第一类医疗器械销售;第二类医疗器械销售;实验分析仪器销售;机械设备销售;电子元器件批发;电子产品销售;计算机软硬件及辅助设备批发;计算机软硬件及辅助设备零售。(除依法须经批准的项目外,凭营业执照依法自主开展经营活动)。
上市日期: 2021-03-25 每股净资产: 47.26元 每股收益: 1.28元 净利润: 1.02亿元 净利润增长率: -92.53%
营业收入: 5.60亿元 每股现金流: -1.06元 每股公积金: 21.57元 每股未分配利润: 22.46元 总股本: 0.79亿 流通股: 0.37亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心